kyprolis
amgen europe b.v. - carfilzomib - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
sarclisa
sanofi winthrop industrie - isatuximab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
flutensif (1.5+5)mg/tab δισκιο ελεγχομενησ αποδεσμευσησ
ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ Ε.Π.Ε. - ΙΝΠΑΠΑΜΙΔΗ, ΒΕΣΥΛΙΚΟ ΑΜΛΟΔΙΠΙΝΗΣ - ΔΙΣΚΙΟ ΕΛΕΓΧΟΜΕΝΗΣ ΑΠΟΔΕΣΜΕΥΣΗΣ - (1.5+5)mg/tab - 0026807658 - indapamide - 1.500000 mg; ineof00344 - amlodipine besylate - 6.935000 mg - amlodipine and diuretics
flutensif (1.5+10)mg/tab δισκιο ελεγχομενησ αποδεσμευσησ
ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ Ε.Π.Ε. - ΙΝΠΑΠΑΜΙΔΗ, ΒΕΣΥΛΙΚΟ ΑΜΛΟΔΙΠΙΝΗΣ - ΔΙΣΚΙΟ ΕΛΕΓΧΟΜΕΝΗΣ ΑΠΟΔΕΣΜΕΥΣΗΣ - (1.5+10)mg/tab - 0026807658 - indapamide - 1.500000 mg; ineof00344 - amlodipine besylate - 13.870000 mg - amlodipine and diuretics